抗肿瘤靶向药物相关不良反应在口腔中的表现及处理对策

doi:10.7518/gjkq.2018.02.004

国际口腔医学杂志 ›› 2018, Vol. 45 ›› Issue (2): 140-144.doi: 10.7518/gjkq.2018.02.004

抗肿瘤靶向药物相关不良反应在口腔中的表现及处理对策

肖妍荻, 杨华梅, 但红霞

口腔疾病研究国家重点实验室国家口腔疾病临床医学研究中心
四川大学华西口腔医院口腔黏膜病科成都 610041

收稿日期:2017-09-14 修回日期:2017-12-27 出版日期:2018-03-01 发布日期:2018-03-01
通讯作者: 但红霞,副教授,博士,Email：hxdan@foxmail.com
作者简介:肖妍荻,硕士,Email：272886584@qq.com
基金资助:
国家自然科学基金（81572663）; 国家卫生与计划生育委员会公益性行业科研专项（201502018）; 国家临床重点专科四川大学华西口腔医院口腔黏膜病科建设经费（2014）

Adverse reactions of targeted anticancer agents in oral cavity: manifestation and management

Xiao Yandi, Yang Huamei, Dan Hongxia

State Key Laboratory of Oral Diseases &National Clinical Research Center for Oral Diseases &Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China

Received:2017-09-14 Revised:2017-12-27 Online:2018-03-01 Published:2018-03-01
Supported by:
Specific Fund of National Health and Family Planning Commission of China (201502018) and National Key Clinical Program on Oral Mucosal Diseases in China (2014).

摘要/Abstract

摘要： 近年来,抗肿瘤靶向药物被广泛应用于临床,其相关的不良反应也引起了学者的重视。口腔是靶向药物不良反应较常累及的部位,本文旨在对抗肿瘤靶向药物相关不良反应在口腔中的表现及处理进行综述,以期能提高临床医生对该现象的认识,提高患者的生存质量。

关键词: 靶向药物, 抗肿瘤治疗, 口腔, 药物不良反应, 处理对策

Abstract: Targeted therapy is widely used in cancer treatment. However, anticancer agents used in targeted therapy can induce various adverse reactions in oral cavity. This review aims to summarize the adverse reactions in oral cavity incurred during targeted therapy and the corresponding strategies for their management.

Key words: targeted agents, anticancer therapy, oral cavity, adverse drug reactions, managing strategies

中图分类号:

R781.5

肖妍荻, 杨华梅, 但红霞. 抗肿瘤靶向药物相关不良反应在口腔中的表现及处理对策[J]. 国际口腔医学杂志, 2018, 45(2): 140-144.

Xiao Yandi, Yang Huamei, Dan Hongxia. Adverse reactions of targeted anticancer agents in oral cavity: manifestation and management[J]. Inter J Stomatol, 2018, 45(2): 140-144.

参考文献

[1] Common terminology criteria for adverse events (CTCAE) version 4.0[S]. Bethesda: National Insti-tutes of Health, National Cancer Institute, 2009.
[2] Vigarios E, Epstein JB, Sibaud V.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors[J]. Support Care Can-cer, 2017, 25(5):1713-1739.
[3] Yuan A, Woo SB.Adverse drug events in the oral cavity[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 119(1):35-47.
[4] Shameem R, Lacouture M, Wu S.Incidence and risk of high-grade stomatitis with mTOR inhibitors in can-cer patients[J]. Cancer Invest, 2015, 33(3):70-77.
[5] Vargo CA, Berger MJ, Phillips G, et al.Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer[J]. Support Care Cancer, 2016, 24(7):2913-2918.
[6] Rugo HS, Hortobagyi GN, Yao J, et al.Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy[J]. Ann Oncol, 2016, 27(3):519-525.
[7] Kaplan B, Qazi Y, Wellen JR.Strategies for the ma-nagement of adverse events associated with mTOR inhibitors[J]. Transplant Rev (Orlando), 2014, 28(3): 126-133.
[8] Soria JC, Felip E, Cobo M, et al.Afatinib versus erlo-tinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2015, 16(8):897-907.
[9] Park K, Tan EH, O’Byrne K, et al. Afatinib versus ge-fitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J]. Lancet Oncol, 2016, 17(5):577-589.
[10] Burotto M, Manasanch EE, Wilkerson J, et al.Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials[J]. Oncologist, 2015, 20(4):400-410.
[11] Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19):1803-1813.
[12] Yamany T, Levender M, Silvers DN, et al.Erythema multiforme-like reaction with mucosal involvement following administration of idelalisib for relapse of chronic lymphocytic leukemia[J]. Leuk Lymphoma, 2015, 56(6):1872-1873.
[13] Edwards D, Boritz E, Cowen EW, et al.Erythema multiforme major following treatment with infliximab[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(2):e36-e40.
[14] Lowndes S, Darby A, Mead G, et al.Stevens-Johnson syndrome after treatment with rituximab[J]. Ann Oncol, 2002, 13(12):1948-1950.
[15] Peterson DE, O’Shaughnessy JA, Rugo HS, et al. Oral mucosal injury caused by mammalian target of rapa-mycin inhibitors: emerging perspectives on pathobio-logy and impact on clinical practice[J]. Cancer Med, 2016, 5(8):1897-1907.
[16] Kuten-Shorrer M, Hochberg EP, Woo SB.Lichenoid mucosal reaction to rituximab[J]. Oncologist, 2014, 19(10):e12-e13.
[17] Zhang JA, Yu JB, Li XH, et al.Oral and cutaneous lichenoid eruption with nail changes due to imatinib treatment in a chinese patient with chronic myeloid leukemia[J]. Ann Dermatol, 2015, 27(2):228-229.
[18] Luo JR, Xiang XJ, Xiong JP.Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor[J]. Int J Clin Pharmacol Ther, 2016, 54(9):719-722.
[19] Bloom MD, Gibney JM, Heldermon CD.Pigmentation of the tongue with lapatinib treatment in a patient with advanced breast cancer: a case report[J]. Cancer Treat Commun, 2016, 7:1-3.
[20] Khoo TL, Catalano A, Supple S, et al.Hyperpigmen-tation of the hard palate associated with imatinib the-rapy for chronic myeloid leukemia with a genetic va-riation in the proto-oncogene c-KIT[J]. Leuk Lym-phoma, 2013, 54(1):186-188.
[21] Li CC, Malik SM, Blaeser BF, et al.Mucosal pigmenta-tion caused by imatinib: report of three cases[J]. Head Neck Pathol, 2012, 6(2):290-295.
[22] Ellis PM, Shepherd FA, Millward M, et al.Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial[J]. Lancet Oncol, 2014, 15(12):1379-1388.
[23] Rizvi NA, Mazières J, Planchard D, et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squa-mous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial[J]. Lancet Oncol, 2015, 16(3):257-265.
[24] Robert C, Schachter J, Long GV, et al.Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372(26):2521-2532.
[25] Boer CC, Correa ME, Miranda EC, et al.Taste dis-orders and oral evaluation in patients undergoing allo-geneic hematopoietic SCT[J]. Bone Marrow Transplant, 2010, 45(4):705-711.
[26] Robert C, Long GV, Brady B, et al.Nivolumab in previously untreated melanoma without BRAF muta-tion[J]. N Engl J Med, 2015, 372(4):320-330.
[27] Tang N, Ratner D.Managing cutaneous side effects from targeted molecular inhibitors for melanoma and nonmelanoma skin cancer[J]. Dermatol Surg, 2016, 42(Suppl 1):S40-S48.
[28] Gavrilovic IT, Balagula Y, Rosen AC, et al.Charac-teristics of oral mucosal events related to bevacizu-mab treatment[J]. Oncologist, 2012, 17(2):274-278.
[29] Hubiche T, Valenza B, Chevreau C, et al.Geographic tongue induced by angiogenesis inhibitors[J]. Oncologist, 2013, 18(4):e16-e17.
[30] Rosen AC, Gavrilovic IT, Balagula Y, et al.In reply[J]. Oncologist, 2013, 18(4):e18.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

抗肿瘤靶向药物相关不良反应在口腔中的表现及处理对策

Adverse reactions of targeted anticancer agents in oral cavity: manifestation and management

RichHTML

PDF (PC)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

Metrics

本文评价

推荐阅读 10

[1]	孔利心,任彪,程磊. 环氧合酶2/前列腺素E₂通路调控口腔肿瘤机制的研究进展[J]. 国际口腔医学杂志, 2020, 47(4): 431-438.
[2]	于林彤,宋光泰. 铒激光在儿童口腔医学中的应用[J]. 国际口腔医学杂志, 2020, 47(3): 351-355.
[3]	易俭如,罗梦奇,尹一佳,刘治清,柳茜,石永乐,杨征,刘帆,韩向龙. 新型冠状病毒肺炎流行期降低口腔诊疗中气溶胶传播风险的策略[J]. 国际口腔医学杂志, 2020, 47(3): 362-365.
[4]	郝福,宁毅,孙睿,郑晓旭. 口腔鳞状细胞癌中转化因子2β的表达及潜在的临床意义[J]. 国际口腔医学杂志, 2020, 47(2): 159-165.
[5]	薛伶俐,李雅冬. 经首次根治性手术治疗口腔鳞状细胞癌患者的生存相关影响因素分析[J]. 国际口腔医学杂志, 2020, 47(2): 166-174.
[6]	田青鹭,赵志河. 微型种植体在口腔正畸中稳定性的研究进展[J]. 国际口腔医学杂志, 2020, 47(2): 212-218.
[7]	魏中武,黄谢山,陈灼庚. 浓缩生长因子在口腔临床中的应用及研究进展[J]. 国际口腔医学杂志, 2020, 47(2): 235-243.
[8]	毕小琴,熊茂婧,陈丽先,白沅艳,田莉,杨晖. 新型冠状病毒肺炎疫情下口腔颌面外科的护理防控[J]. 国际口腔医学杂志, 2020, 47(2): 244-248.
[9]	张明爽,巴特,王文标. 口腔微生物种群与阿尔茨海默病相关发病机制的研究进展[J]. 国际口腔医学杂志, 2020, 47(1): 102-108.
[10]	崔钰嘉,孙建勋,周学东. 黄连素的生物学功能及治疗口腔疾病研究的进展[J]. 国际口腔医学杂志, 2020, 47(1): 115-120.
[11]	董云梅,陶艳,周瑜. 口腔黏膜癌变过程中血清生化标志物的研究进展[J]. 国际口腔医学杂志, 2020, 47(1): 43-50.
[12]	陈煜鑫,周瑜,陈谦明. 口腔苔藓样病变的研究进展[J]. 国际口腔医学杂志, 2020, 47(1): 51-57.
[13]	沈晨露,叶伟佳,吕柯佳,高碧聪,姚华. 口腔扁平苔藓实验模型建立的研究进展[J]. 国际口腔医学杂志, 2020, 47(1): 58-62.
[14]	黄璐,戴杰,吴燕岷. 唾液生物标志物在口腔癌筛查中的应用[J]. 国际口腔医学杂志, 2020, 47(1): 68-75.
[15]	陈宏丽,杨敬,尹刚,李皓缘,乔燕. 锌指蛋白32在口腔鳞状细胞癌中的表达意义及对口腔鳞状细胞癌干细胞的影响[J]. 国际口腔医学杂志, 2019, 46(6): 631-639.